Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.

Wadden TA, Walsh OA, Berkowitz RI, Chao AM, Alamuddin N, Gruber K, Leonard S, Mugler K, Bakizada Z, Tronieri JS

Obesity (Silver Spring, Md.)13 Nov 2018Cited by 78 (Europe PMC)

PMID30421856PMCIDPMC6800068DOI10.1002/oby.22359PepBankPUB-30421856

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, adding liraglutide 3.0 mg to intensive behavioral therapy gave greater 1-year weight loss than intensive behavioral therapy alone.
In plain wordsIn adults with obesity, adding liraglutide to intensive behavioral therapy led to more weight loss after 1 year than the therapy alone.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at 1 year, IBT-liraglutide versus IBT-alone
Study
n: not reported in source
Comparator
Intensive behavioral therapy alone
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 1 yearAs given in this study (human).
Measurements
Weight loss
11.5%
IBT-liraglutide
Weight loss
6.1%
IBT-alone
Source sentences
Summary
Ninety-one percent of participants completed 1 year, at which time mean (± SEM) losses for IBT-alone, IBT-liraglutide, and Muticomponent participants were 6.1 ± 1.3%, 11.5 ± 1.3%, and 11.8 ± 1.3% of baseline weight, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The liraglutide-treated groups were superior to IBT-alone on both outcomes.
Summary · context
The 1-year trial also assessed whether the addition to IBT of liraglutide 3.0 mg would significantly increase weight loss and whether the provision of meal replacements would add further benefit.
Summary · context
A total of 150 adults with obesity were randomly assigned to: IBT (IBT-alone), providing 21 counseling visits; IBT combined with liraglutide (IBT-liraglutide); or IBT-liraglutide combined for 12 weeks with a 1,000- to 1,200-kcal/d meal-replacement diet (Multicomponent).
Report a problemFND-3042185601
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity, more participants lost 5% or more of weight with intensive behavioral therapy plus liraglutide 3.0 mg than with therapy alone.
In plain wordsIn adults with obesity, more people lost at least 5% of their weight with liraglutide plus behavioral therapy than with the therapy alone.
Peptide
Liraglutide
Outcome
IncreaseProportion with weight loss of 5% or more at 1 year, IBT-liraglutide versus IBT-alone
Study
n: not reported in source
Comparator
Intensive behavioral therapy alone
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 1 yearAs given in this study (human).
Measurements
Participants with weight loss of 5% or more
70%
IBT-liraglutide
Participants with weight loss of 5% or more
44%
IBT-alone
Source sentences
Summary
Fully 44.0%, 70.0%, and 74.0% of these participants lost ≥ 5% of weight, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The liraglutide-treated groups were superior to IBT-alone on both outcomes.
Summary · context
The 1-year trial also assessed whether the addition to IBT of liraglutide 3.0 mg would significantly increase weight loss and whether the provision of meal replacements would add further benefit.
Summary · context
A total of 150 adults with obesity were randomly assigned to: IBT (IBT-alone), providing 21 counseling visits; IBT combined with liraglutide (IBT-liraglutide); or IBT-liraglutide combined for 12 weeks with a 1,000- to 1,200-kcal/d meal-replacement diet (Multicomponent).
Report a problemFND-3042185602

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, weight loss in all three groups, including intensive behavioral therapy alone, was associated with clinically meaningful improvements in cardiometabolic risk factors.
In plain wordsIn adults with obesity, weight loss in all three groups was linked to better heart and metabolic risk factors, not only with liraglutide.
Peptide
Liraglutide
Outcome
Not applicableCardiometabolic risk factors with weight loss in all three groups
Study
n = 150
Outcome group
Cardiometabolic risk factors · Cardiovascular
Source sentences
Summary
Weight loss in all three groups was associated with clinically meaningful improvements in cardiometabolic risk factors.
2 context sentences(design, population, supporting numbers)
Summary · context
The 1-year trial also assessed whether the addition to IBT of liraglutide 3.0 mg would significantly increase weight loss and whether the provision of meal replacements would add further benefit.
Summary · context
A total of 150 adults with obesity were randomly assigned to: IBT (IBT-alone), providing 21 counseling visits; IBT combined with liraglutide (IBT-liraglutide); or IBT-liraglutide combined for 12 weeks with a 1,000- to 1,200-kcal/d meal-replacement diet (Multicomponent).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3042185605
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, a regimen of intensive behavioral therapy, liraglutide 3.0 mg and a 12-week meal-replacement diet gave greater 1-year weight loss than intensive behavioral therapy alone.
In plain wordsIn adults with obesity, behavioral therapy plus liraglutide and meal replacements led to more weight loss after 1 year than behavioral therapy alone.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at 1 year, Multicomponent versus IBT-alone
Study
n: not reported in source
Comparator
Intensive behavioral therapy alone
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
11.8%
Multicomponent
Weight loss
6.1%
IBT-alone
Source sentences
Summary
Ninety-one percent of participants completed 1 year, at which time mean (± SEM) losses for IBT-alone, IBT-liraglutide, and Muticomponent participants were 6.1 ± 1.3%, 11.5 ± 1.3%, and 11.8 ± 1.3% of baseline weight, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The liraglutide-treated groups were superior to IBT-alone on both outcomes.
Summary · context
The 1-year trial also assessed whether the addition to IBT of liraglutide 3.0 mg would significantly increase weight loss and whether the provision of meal replacements would add further benefit.
Summary · context
A total of 150 adults with obesity were randomly assigned to: IBT (IBT-alone), providing 21 counseling visits; IBT combined with liraglutide (IBT-liraglutide); or IBT-liraglutide combined for 12 weeks with a 1,000- to 1,200-kcal/d meal-replacement diet (Multicomponent).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3042185603
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, more participants lost 5% or more of weight with intensive behavioral therapy, liraglutide 3.0 mg and meal replacements than with therapy alone.
In plain wordsIn adults with obesity, more people lost at least 5% of their weight with behavioral therapy, liraglutide and meal replacements than with therapy alone.
Peptide
Liraglutide
Outcome
IncreaseProportion with weight loss of 5% or more at 1 year, Multicomponent versus IBT-alone
Study
n: not reported in source
Comparator
Intensive behavioral therapy alone
Outcome group
Body weight · Metabolic and weight
Measurements
Participants with weight loss of 5% or more
74%
Multicomponent
Participants with weight loss of 5% or more
44%
IBT-alone
Source sentences
Summary
Fully 44.0%, 70.0%, and 74.0% of these participants lost ≥ 5% of weight, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The liraglutide-treated groups were superior to IBT-alone on both outcomes.
Summary · context
The 1-year trial also assessed whether the addition to IBT of liraglutide 3.0 mg would significantly increase weight loss and whether the provision of meal replacements would add further benefit.
Summary · context
A total of 150 adults with obesity were randomly assigned to: IBT (IBT-alone), providing 21 counseling visits; IBT combined with liraglutide (IBT-liraglutide); or IBT-liraglutide combined for 12 weeks with a 1,000- to 1,200-kcal/d meal-replacement diet (Multicomponent).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3042185604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT02911818

Lifestyle Modification and Liraglutide

University of Pennsylvanian = 150Sept 2016 to Dec 2018

Obesity

Trial page ClinicalTrials.govUpdated 7 May 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.